Search ↗

Comparison

GHK-Cu vs TB-500

Both are healing & repair, so the meaningful differences are in kinetics, evidence and regulatory status.

On published evidence alone, GHK-Cu is the better documented of the two (clinical trials). That is a statement about the state of the literature, not a recommendation.

GHK-Cu TB-500
Class Healing & repair Healing & repair
Evidence Clinical trials Preliminary human
Human trials ~15 ~4
Half-life ~30 minutes (systemic) ~2-3 hours
Reported range 1-2 mg 2-5 mg
Frequency Daily topical, or subcutaneous in research protocols 2x weekly loading, then weekly
Routes Topical, Subcutaneous Subcutaneous, Intramuscular
FDA approved No No
Research use only No Yes
Banned in sport No Yes
Studied for Skin repair and anti-ageing, Wound healing, Hair follicle stimulation Soft tissue repair research, Wound healing, Cardiac repair research
Reported side effects Local irritation, Transient redness, Injection-site reactions Injection-site reactions, Transient fatigue, Head rush, Mild nausea

GHK-Cu

GHK is a tripeptide present in human plasma that declines markedly with age, and it binds copper(II) with high affinity to form GHK-Cu. The complex modulates expression of a large set of genes involved in tissue remodelling, stimulating collagen, elastin and glycosaminoglycan synthesis while influencing antioxidant and anti-inflammatory pathways. Its dermatological evidence is comparatively strong and includes controlled human trials; the systemic injectable use is far less supported.

TB-500

TB-500 is the synthetic form of thymosin beta-4, a 43-residue peptide whose principal activity is sequestering G-actin and regulating cytoskeletal assembly. That function underlies its reported effects on cell migration, angiogenesis and wound repair, with the LKKTETQ heptapeptide identified as the active binding region. Human data exists from small trials in dry eye and pressure ulcers; the musculoskeletal claims that drive its popularity rest on animal models.

GHK-Cu vs TB-500: common questions

What is the difference between GHK-Cu and TB-500?

Both are healing & repair. GHK-Cu: A naturally occurring copper-binding tripeptide with the strongest human evidence base of any compound in the healing group, mostly topical. TB-500: A synthetic version of thymosin beta-4, the actin-sequestering peptide most often paired with BPC-157.

Which has stronger evidence, GHK-Cu or TB-500?

GHK-Cu has the stronger evidence base (clinical trials, about 15 human studies) compared with TB-500 (preliminary human).

Are GHK-Cu and TB-500 FDA approved?

Neither is FDA approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 139035031) ↗ · structure, identifiers, synonyms
  2. CAS Registry Number 89030-95-5 ↗ · chemical identity
  3. PubChem compound record (CID 62707662) ↗ · structure, identifiers, synonyms
  4. WADA Prohibited List ↗ · current year
  5. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  6. CAS Registry Number 77591-33-4 ↗ · chemical identity

Published literature

  1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.Int J Mol Sci 2018.PubMed 29986520 · doi:10.3390/ijms19071987
  2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.Biomed Res Int 2015.PubMed 26236730 · doi:10.1155/2015/648108
  3. Mayfield CK, Bolia IK, Feingold CL, et al.. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.Am J Sports Med 2026.PubMed 41476424 · doi:10.1177/03635465251357593
  4. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  5. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  6. Ogórek K, Nowak K, Wadych E, et al.. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?.Molecules 2025.PubMed 39795193 · doi:10.3390/molecules30010136
  7. Pickart L. The human tri-peptide GHK and tissue remodeling.J Biomater Sci Polym Ed 2008.PubMed 18644225 · doi:10.1163/156856208784909435
  8. Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci 2026.PubMed 42123471 · doi:10.3390/ijms27093890
  9. Sun HQ, Yin HL. The beta-thymosin enigma.Ann N Y Acad Sci 2007.PubMed 17495248 · doi:10.1196/annals.1415.021
  10. Hannappel E. beta-Thymosins.Ann N Y Acad Sci 2007.PubMed 17468232 · doi:10.1196/annals.1415.018
  11. Fox JE. The platelet cytoskeleton.Thromb Haemost 1993.PubMed 8165606
  12. Gebran S, Romano E, Soyano A. [Biomolecules suppressing myelopoiesis].Acta Cient Venez 1992.PubMed 1343739
  13. Kleinman HK, Sosne G. Thymosin β4 Promotes Dermal Healing.Vitam Horm 2016.PubMed 27450738 · doi:10.1016/bs.vh.2016.04.005

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.